Jarushka Naidoo

Sherlock-Lung: Mutagenesis of LC in Never Smokers (LCNS) ⁦⁦@Nature⁩: - 871pt samples - KRAS+ ⬆️3.8x in LCNS’s in USA/EU v Asia - passive smoke not assoc with mtns - air pollution (PM2.5) assoc with p53 & shorter telomeres ⁦@OncoAlert⁩ #LCSM nature.com/articles/s4158…

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team…

News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…

Out now in @JCO_ASCO, v2025.1 of @ASCO Living Guideline for Stage 4 NSCLC w/ driver mutation. ascopubs.org/doi/pdf/10.120…. key updates: ✅incorporation of zenocutuzumab for NRG1-fusion+ NSCLC. ✅commentary on ph2 RAMOSE trial. For concise summary, ✔️ out @ASCO guidelines podcast

Behind every biomarker is a person. It was an honor to co-author this comprehensive review on optimizing treatment for #EGFRm #NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… It isn't easy for a patient/advocate to contribute meaningfully to long, technical articles, but that's exactly why…

Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer - 18m-PFS 65.5% N, 66.3% I/N - mOS 32m, NR - g3+ TRAE 18.5% v 29.4% Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI jitc.bmj.com/content/13/7/e…

🚨 Just out in @JTOonline! A must-read review from the @IASLC Communications Committee: 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic jto.org/article/S1556-… 🧭 A fast-track tour in #LungCancer, from staging to immunotherapy. Perfect to breathe in the past…

50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow’s Guide in the Clinic jto.org/article/S1556-… via @DrJNaidoo et al

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, @StephenVLiu, @MariamAlex26 & Dr. James Chih-Hsin Yang break down the data and explore clinical impact. 🎧 bit.ly/FDAexon20

In the Diary of an Oncology Leader video series by #ESMOW4O @marinagarassino shares the key lessons that continue to influence her leadership style 👉 Stay tuned for the next episode featuring @DrAngelaLamarca 🔗 ow.ly/iC0350Wp6Oe #ESMODailyReporter #OncologyLeadership

🚨 Just published! TP53 co-mutations significantly increase the risk of recurrence in stage I EGFR-mutated LUAD. 🔬 Worse RFS, similar OS → supports the need for treatment escalation even in early-stage disease. sciencedirect.com/science/articl…

Superb @etop_ibcsg T-cell engager workshop exploring next steps in thoracic tumors & academic trials. Stellar talks, including - TCEs in thoracic Onc @peters_solange - Genomics of SCLC #RamGovindan - Biomarkers in SCLC @triparnasen Thanks to the scientific committee #LCSM

‘EAGLE-AI’ dig path-AI predicts EGFRmtns in NSCLC ⁦⁦@NatureMedicine⁩ - assessment of 1642 H&E slides, with external (4 cohort) & prospective validation (AUC 0.83) - median turnaround time:44mins Wow @OncoAlert⁩ ⁦@MSKCancerCenter⁩ #LCSM nature.com/articles/s4159…

Meet me in DC. I'll be the very caffeinated person running to attend the presentations of all of the brilliant people I follow here. Let's discuss quality of life off of the web: QOL in IRL , and any more acronyms you can think up, I'm up for it. #LungCancer @EGFRResisters…

🚨 TODAY Our roundtable with @GautschiOliver, @DrJNaidoo, and @nicogirardcurie on targeted therapies in ALK+ and EGFR+ NSCLC starts soon. Don’t miss this chance to explore resistance, combinations, and novel agents and earn CME credits in the process ✅ ⬇️ Today at 5PM CEST

The latest episode of the @IASLC podcast previews the upcoming #WCLC25 meeting with the four co-chairs: Drs. @DrJNaidoo @UmbertoMalapel1 @IsaOpitz @NReguart being held September 6-9, 2025 in Barcelona. Registration open now! iaslc.org/iaslc-news/lun…

Thanks to @StephenVLiu & @NarjustFlorezMD for the opportunity to showcase the upcoming @IASLC #WCLC25 conference in Barcelona Join us Sept 6-9, for the very best in thoracic oncology @NReguart @IsaOpitz @UmbertoMalapel1 #LCSM

REMINDER: Apply now for our 14th ETOP Residential Workshop. Deadline is 31st July.

Join us at #DCLung25 on Saturday, October 4th in downtown Washington, DC for the latest updates in lung cancer. Dr. Jarushka Naidoo @DrJNaidoo joins the faculty to discuss immunotherapy toxicity. @IASLC endorsed & CME / MOC credits - register today! medstarhealth.org/dclung25